NCT00508807View on ClinicalTrials.gov

RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Lymphoid MalignanciesSolid Tumors
Interventions
DRUG

RTA 402

5 mg by mouth (PO) daily for 21 days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Reata Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00508807 - RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies | Biotech Hunter | Biotech Hunter